Nouvelles molécules et thérapeutiques moléculaires ciblées dans les adénocarcinomes ovariens de stades avancés

Rouge, Thibault De La Motte; Petrella, Maria Cristina; Michels, Judith; Even, Caroline; Balleyguier, Corinne; Duclos, J Y; Mazeron, R.; Morice, Philippe; Lhommé, C.

doi:10.1684/bdc.2009.0988

Cited by 5 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of reports have reinforced the notion that inhibition of a single transduction pathway may be insufficient since activation of alternative signaling cascades may conceal efficacy, and that it would be more advantageous to target integrated cancer signals, for example, VEGFR- and EGFR-interdependent pathways [170] and heparin-binding epidermal growth factor-like growth factor (HB-EGF) [200, 201]. Remarkably also, the mammalian target of rapamycin (mTOR) is a central intracellular kinase that not only orchestrates proliferation, survival, and angiogenic pathways, but has also been linked to resistance to EGFR antagonists, and thus mTOR inhibition could be explored to interfere with tumor growth and expansion at multiple levels [4, 83, 84, 92, 159, 170, 202–205]. Another multiple molecular targeting platform is provided by EGFR-induced EMT in EOC, possibly via mechanisms that incorporate estrogen signaling, E-cadherin downregulation and expression of matrix metalloproteinase-9 (MMP-9), and Snail transcription family members (SNAIL and SLUG) [79, 206, 207].…”

Section: Ovarian Cancer Biomarkers and Cellsignaling Pathwaysmentioning

confidence: 99%

Optimizing Molecular-Targeted Therapies in Ovarian Cancer: The Renewed Surge of Interest in Ovarian Cancer Biomarkers and Cell Signaling Pathways

Hiss

2012

Journal of Oncology

View full text Add to dashboard Cite

The hallmarks of ovarian cancer encompass the development of resistance, disease recurrence and poor prognosis. Ovarian cancer cells express gene signatures which pose significant challenges for cancer drug development, therapeutics, prevention and management. Despite enhancements in contemporary tumor debulking surgery, tentative combination regimens and abdominal radiation which can achieve beneficial response rates, the majority of ovarian cancer patients not only experience adverse effects, but also eventually relapse. Therefore, additional therapeutic possibilities need to be explored to minimize adverse events and prolong progression-free and overall response rates in ovarian cancer patients. Currently, a revival in cancer drug discovery is devoted to identifying diagnostic and prognostic ovarian cancer biomarkers. However, the sensitivity and reliability of such biomarkers may be complicated by mutations in the BRCA1 or BRCA2 genes, diverse genetic risk factors, unidentified initiation and progression elements, molecular tumor heterogeneity and disease staging. There is thus a dire need to expand existing ovarian cancer therapies with broad-spectrum and individualized molecular targeted approaches. The aim of this review is to profile recent developments in our understanding of the interrelationships among selected ovarian tumor biomarkers, heterogeneous expression signatures and related molecular signal transduction pathways, and their translation into more efficacious targeted treatment rationales.

show abstract

Section: Ovarian Cancer Biomarkers and Cellsignaling Pathwaysmentioning

confidence: 99%

Optimizing Molecular-Targeted Therapies in Ovarian Cancer: The Renewed Surge of Interest in Ovarian Cancer Biomarkers and Cell Signaling Pathways

Hiss

2012

Journal of Oncology

View full text Add to dashboard Cite

show abstract

Angiogenesis and molecular markers in advanced epithelial ovarian cancer: A retrospective study

Ferrero

Dompè

Ravarino

et al. 2011

Gynecologic Oncology

View full text Add to dashboard Cite

Stem cells’ guided gene therapy of cancer: New frontier in personalized and targeted therapy

Mavroudi¹,

Porpodis²,

Kioumis³

et al. 2014

J Cancer Res Ther

View full text Add to dashboard Cite

Introduction Diagnosis and therapy of cancer remain to be the greatest challenges for all physicians working in clinical oncology and molecular medicine. The statistics speak for themselves with the grim reports of 1,638,910 men and women diagnosed with cancer and nearly 577,190 patients passed away due to cancer in the USA in 2012. For practicing clinicians, who treat patients suffering from advanced cancers with contemporary systemic therapies, the main challenge is to attain therapeutic efficacy, while minimizing side effects. Unfortunately, all contemporary systemic therapies cause side effects. In treated patients, these side effects may range from nausea to damaged tissues. In cancer survivors, the iatrogenic outcomes of systemic therapies may include genomic mutations and their consequences. Therefore, there is an urgent need for personalized and targeted therapies. Recently, we reviewed the current status of suicide gene therapy for cancer. Herein, we discuss the novel strategy: genetically engineered stem cells’ guided gene therapy. Review of therapeutic strategies in preclinical and clinical trials Stem cells have the unique potential for self renewal and differentiation. This potential is the primary reason for introducing them into medicine to regenerate injured or degenerated organs, as well as to rejuvenate aging tissues. Recent advances in genetic engineering and stem cell research have created the foundations for genetic engineering of stem cells as the vectors for delivery of therapeutic transgenes. Specifically in oncology, the stem cells are genetically engineered to deliver the cell suicide inducing genes selectively to the cancer cells only. Expression of the transgenes kills the cancer cells, while leaving healthy cells unaffected. Herein, we present various strategies to bioengineer suicide inducing genes and stem cell vectors. Moreover, we review results of the main preclinical studies and clinical trials. However, the main risk for therapeutic use of stem cells is their cancerous transformation. Therefore, we discuss various strategies to safeguard stem cell guided gene therapy against iatrogenic cancerogenesis. Perspectives Defining cancer biomarkers to facilitate early diagnosis, elucidating cancer genomics and proteomics with modern tools of next generation sequencing, and analyzing patients’ gene expression profiles provide essential data to elucidate molecular dynamics of cancer and to consider them for crafting pharmacogenomics-based personalized therapies. Streamlining of these data into genetic engineering of stem cells facilitates their use as the vectors delivering therapeutic genes into specific cancer cells. In this realm, stem cells guided gene therapy becomes a promising new frontier in personalized and targeted therapy of cancer.

show abstract

Nouvelles molécules et thérapeutiques moléculaires ciblées dans les adénocarcinomes ovariens de stades avancés

Cited by 5 publications

References 0 publications

Optimizing Molecular-Targeted Therapies in Ovarian Cancer: The Renewed Surge of Interest in Ovarian Cancer Biomarkers and Cell Signaling Pathways

Optimizing Molecular-Targeted Therapies in Ovarian Cancer: The Renewed Surge of Interest in Ovarian Cancer Biomarkers and Cell Signaling Pathways

Angiogenesis and molecular markers in advanced epithelial ovarian cancer: A retrospective study

Stem cells’ guided gene therapy of cancer: New frontier in personalized and targeted therapy

Contact Info

Product

Resources

About